Retatrutide Research

The History of Retatrutide

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-234 cited sources

The short answer

Retatrutide was described by Coskun and colleagues in Cell Metabolism in September 2022. Phase 2 results appeared in the New England Journal of Medicine in 2023, and the Phase 3 TRIUMPH programme reported from December 2025 through July 2026, with an FDA filing signalled for Q1 2027.

Key facts

Discovery paper
Coskun, Cell Metab, Sept 2022
Phase 2
Jastreboff, NEJM 2023 (PMID 37366315)
Phase 2 in T2D
Rosenstock, Lancet 2023 (PMID 37385280)
First Phase 3 readout
TRIUMPH-4, December 2025
Pivotal readout
TRIUMPH-1, 21 May 2026
Signalled FDA filing
Q1 2027
Approvals
None, anywhere

The discovery paper

Coskun and colleagues published LY3437943's discovery and characterisation in Cell Metabolism in September 2022, subtitled from discovery to clinical proof of concept. It describes the design objective (balanced agonism across GIP, GLP-1 and glucagon receptors) and the pharmacology achieved. It remains the primary structural reference.

Phase 2 and the numbers that drew attention

Jastreboff and colleagues reported the Phase 2 obesity trial in the New England Journal of Medicine in 2023, and Rosenstock and colleagues reported in adults with type 2 diabetes in the Lancet the same year. The obesity figures were the largest then reported for any single-molecule incretin agonist, which is what made retatrutide the compound the field watched.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The Phase 3 programme

TRIUMPH enrolled more than 5,800 participants. TRIUMPH-4 reported first in December 2025. TRIUMPH-1, the pivotal obesity study, reported on 21 May 2026. TRIUMPH-2 and TRIUMPH-3 followed in July 2026, covering type 2 diabetes and established cardiovascular disease. All met their primary endpoints.

Where it stands now

Investigational everywhere. Lilly has signalled a Biologics License Application to the FDA in the first quarter of 2027, and no MHRA or EMA timeline has been announced. Further readouts including maintenance-dosing studies remain outstanding; TRIUMPH-6 has a primary completion date of April 2028.

A citation worth getting right

The two Phase 2 papers are frequently miscited. Jastreboff's NEJM paper is PMID 37366315 and Rosenstock's Lancet paper is PMID 37385280. This library previously carried neighbouring PMIDs that resolved to a paediatric ophthalmology paper and a cardiothoracic surgery commentary. They were corrected earlier this week, and are a reasonable illustration of how easily a plausible-looking identifier goes wrong.

Frequently asked questions

When was retatrutide first described?

Coskun and colleagues published its discovery in Cell Metabolism in September 2022.

Has it been approved anywhere?

No. It remains investigational in every jurisdiction, with an FDA filing signalled for Q1 2027.

What is still outstanding?

Maintenance-dosing data. TRIUMPH-6 has a primary completion date of April 2028.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More Retatrutide Research articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.